Oppenheimer Asset Management Has Cut Genesee & Wyo (GWR) Holding; Xbiotech (XBIT) Shorts Lowered By 2.23%

January 13, 2018 - By Clifton Ray

Oppenheimer Asset Management Inc decreased Genesee & Wyo Inc (GWR) stake by 68.59% reported in 2017Q3 SEC filing. Oppenheimer Asset Management Inc sold 4,317 shares as Genesee & Wyo Inc (GWR)’s stock declined 14.44%. The Oppenheimer Asset Management Inc holds 1,977 shares with $146,000 value, down from 6,294 last quarter. Genesee & Wyo Inc now has $5.19B valuation. The stock decreased 0.48% or $0.4 during the last trading session, reaching $83.13. About 343,526 shares traded. Genesee & Wyoming Inc. (NYSE:GWR) has risen 13.88% since January 13, 2017 and is uptrending. It has underperformed by 2.82% the S&P500.

Xbiotech Incorporated (NASDAQ:XBIT) had a decrease of 2.23% in short interest. XBIT’s SI was 6.02M shares in January as released by FINRA. Its down 2.23% from 6.16M shares previously. With 68,000 avg volume, 89 days are for Xbiotech Incorporated (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Incorporated’s float is 36.16%. The stock increased 0.73% or $0.03 during the last trading session, reaching $4.16. About 70,198 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 37.97% since January 13, 2017 and is downtrending. It has underperformed by 54.67% the S&P500.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $147.42 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Since August 14, 2017, it had 0 insider buys, and 6 insider sales for $2.06 million activity. Brown David A also sold $275,086 worth of Genesee & Wyoming Inc. (NYSE:GWR) shares. On Tuesday, August 29 the insider Walsh Matthew O. sold $255,250. Another trade for 5,073 shares valued at $339,079 was made by Gallagher Timothy J on Monday, August 14. On Friday, August 25 the insider HELLMANN JOHN C sold $926,918. Shares for $168,443 were sold by Fergus Allison M. Another trade for 1,401 shares valued at $93,755 was sold by Liucci Christopher F.

Analysts await Genesee & Wyoming Inc. (NYSE:GWR) to report earnings on February, 14. They expect $0.75 earnings per share, down 24.24% or $0.24 from last year’s $0.99 per share. GWR’s profit will be $46.79M for 27.71 P/E if the $0.75 EPS becomes a reality. After $0.81 actual earnings per share reported by Genesee & Wyoming Inc. for the previous quarter, Wall Street now forecasts -7.41% negative EPS growth.

Investors sentiment increased to 1.07 in 2017 Q3. Its up 0.08, from 0.99 in 2017Q2. It is positive, as 27 investors sold GWR shares while 82 reduced holdings. 37 funds opened positions while 80 raised stakes. 58.92 million shares or 1.22% more from 58.21 million shares in 2017Q2 were reported. Brown Advisory has invested 0% in Genesee & Wyoming Inc. (NYSE:GWR). Franklin Resources Inc invested in 837,847 shares. Commonwealth Of Pennsylvania School Empls Retrmt stated it has 0.01% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Jupiter Asset Mgmt Limited holds 0.23% or 91,737 shares. Symphony Asset Mgmt Limited Liability Corporation has invested 0.06% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Fifth Third National Bank, a Ohio-based fund reported 300 shares. Rmb Cap Mgmt Ltd Liability Company reported 0.62% stake. Advantus Cap Management has invested 0.01% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR). Royal Bancorp Of Canada invested 0% in Genesee & Wyoming Inc. (NYSE:GWR). Moreover, Snyder Capital LP has 1.74% invested in Genesee & Wyoming Inc. (NYSE:GWR) for 469,494 shares. Hightower Advsr Lc accumulated 33,264 shares. Cardinal Capital Mgmt Lc Ct invested in 1.18M shares. Aperio Gp Ltd holds 0.01% in Genesee & Wyoming Inc. (NYSE:GWR) or 21,439 shares. Bbva Compass Bankshares reported 0.02% stake. Dimensional Fund Advsrs LP holds 0.05% of its portfolio in Genesee & Wyoming Inc. (NYSE:GWR) for 1.59M shares.

Among 13 analysts covering Genesee & Wyoming Inc. (NYSE:GWR), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Genesee & Wyoming Inc. had 39 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Genesee & Wyoming Inc. (NYSE:GWR) earned “Outperform” rating by Cowen & Co on Wednesday, May 3. The stock of Genesee & Wyoming Inc. (NYSE:GWR) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, February 23. The stock has “Buy” rating by J.P. Morgan on Tuesday, January 9. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Thursday, January 7 report. The stock of Genesee & Wyoming Inc. (NYSE:GWR) earned “Sector Perform” rating by RBC Capital Markets on Friday, April 29. The rating was maintained by Cowen & Co on Monday, November 2 with “Outperform”. The rating was upgraded by Macquarie Research on Monday, November 2 to “Outperform”. As per Friday, September 29, the company rating was maintained by Cowen & Co. Stephens maintained Genesee & Wyoming Inc. (NYSE:GWR) on Monday, December 14 with “Outperform” rating. On Tuesday, August 4 the stock rating was maintained by RBC Capital Markets with “Top Pick”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News